Open-label, long-term, efficacy, safety, and tolerability extension study using the pediatric formulation of bosentan in the treatment of Japanese children with pulmonary arterial hypertension who completed the previous study.
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Bosentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Actelion Pharmaceuticals
- 13 Sep 2016 Status changed from active, no longer recruiting to completed.
- 01 Jun 2016 New trial record